September 21, 2022

MultiplexDX helped to open a new Biochemistry lab for young students and potential future scientists

Our CEO, dr. Pavol Cekan was present at the ceremonial opening of the Section of new STEM-oriented technical classrooms, including the Biochemistry laboratory, of which he became the protector.

The new Biochemistry lab in primary school in Vranov and Toplou in the East part of Slovakia is an excellent opportunity for young students to learn more about chemistry and biology through experiments. This might be the place where students will fall in love with chemistry or biology and discover their passion for science. In an ideal case, those young students will become top scientists in the future.

After the official ceremony, there was a discussion with our CEO, dr. Pavol Cekan, and students about his scientific work abroad, the innovation part MultiplexDX company works on, and many more topics students were curious to discuss.

MultiplexDX donated to the laboratory brand new lab coats. The project aims to impact the quality of the educational process in STEM-oriented disciplines and increase students' interest in natural sciences, which might shape their future professional careers.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News